RxDoctor Payments Data

Olga Matsibekker, MD

Internal Medicine · Brooklyn, NYNPI 1952403156

Payments from drug & device makers

$2,259in general payments, 2019–2025

Across 22 payments — averaging $102.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$809
  • AstraZeneca$488
  • GSK$250
  • Amgen$247
  • Lilly USA, LLC$125
  • Merck$125
  • plus $215 from 2 others

What the payments were for

  • Food & beverage$2,259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$809
AstraZeneca4$488
GSK2$250
Amgen2$247
Lilly USA, LLC1$125
Merck1$125
Novartis1$120
AbbVie4$95

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,259 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$26,296
Medicare patients
90
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide185$180,983
JardianceEmpagliflozin117$78,991
TrulicityDulaglutide63$73,495
EliquisApixaban75$57,686
JanuviaSitagliptin Phosphate50$56,342
MounjaroTirzepatide44$48,525
EntrestoSacubitril/Valsartan63$43,606
LinzessLinaclotide49$31,353
ProliaDenosumab18$29,139
TradjentaLinagliptin32$20,204
XareltoRivaroxaban23$19,023
Spiriva HandihalerTiotropium Bromide36$18,180
VascepaIcosapent Ethyl39$16,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,631
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$11,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$809$180,983185 claims
Lilly USA, LLCTrulicity, Mounjaro$125$122,020107 claims
MerckJanuvia, Steglatro$125$60,35062 claims
NovartisEntresto$120$43,60663 claims
AbbVieLinzess, Creon, Synthroid$95$42,13795 claims
AmgenProlia$247$29,13918 claims
GSKTrelegy Ellipta$250$15,63124 claims
AstraZenecaNexium$488$4,76119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →